Home › Funds › PSP Research LLC › CRNX
PSP Research LLC position in CRNX
CRINETICS PHARMACEUTICALS IN
PSP Research LLC reported holding 11,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$412K, representing 0.22% of its reported portfolio and ranking #32 among its reported holdings. PSP Research LLC has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
How PSP Research LLC's CRNX position evolved
PSP Research LLC first disclosed a stake in CRNX in Q4 2025 at 11,316 shares (US$527K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 11,000 shares valued at US$412K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 11.32K | $526.76K | New |
| Q1 2026 | 11.00K | $399.52K | Reduce |
| Q2 2026 | 11.00K | $411.62K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026